Adalimumab is the most used of the biologics for the treatment of
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- It is an anti-TNF antibody that counteracts inflammation.
- It is administered through subcutaneous injection every 2 weeks.
- In 2016, its sales in Europe amounted to €2.8 billion.
- A high percentage of patients form ADAs against this drug, between 20-53%.
Labs that test for drug level:
Labs that test for ADA titre: